A carregar...
Publicação
Major challenges in Rheumatology: will we ever treat smarter, instead of just harder?
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 272.15 KB | Adobe PDF |
Orientador(es)
Resumo(s)
The field of rheumatology has witnessed astonishing progress in the understanding and management of rheumatic diseases since the second half of the twentieth century. The discovery and introduction of glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) into the therapeutic armamentarium of rheumatologists enabled, for the first time, to effectively change the natural course of disease and improve most clinical outcomes. The new millennium pushed the revolution further at an exponential level with the advent of sophisticated, biologically-engineered drugs—the so-called biologicals or bDMARDs—that targeted specific molecules in key pathogenic pathways and dramatically modified the prognosis of most patients with immune-mediated rheumatic diseases.
Descrição
Copyright © 2019 Romão and Fonseca. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Palavras-chave
Biomarkers Personalized medicine Rheumatoid arthritis Rheumatology Stratification
Contexto Educativo
Citação
Front Med (Lausanne). 2019 Jun 26;6:144
Editora
Frontiers